NMDA Receptor Modulation for Hyperarousal in PTSD

Trial Profile

NMDA Receptor Modulation for Hyperarousal in PTSD

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Lanicemine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2018 Planned initiation date changed from 1 Sep 2017 to 1 May 2018.
    • 31 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top